AGÕæÈ˹ٷ½

Lantern Pharma Inc. (LTRN) filed a preliminary proxy (Form PRE-14A) for its virtual 2025 Annual Meeting, scheduled 19 September 2025 at 11:00 a.m. ET. Holders of record on 28 July 2025 will vote on four proposals:

• Elect six directors (current slate; five qualify as independent).
• Reprice 314,633 underwater stock options (â‰�25 % of total outstanding options). Grants with strikes >$10 will reset to $5.04â€�125 % of the 10-day VWAP—if holders remain employed/serving for 12 months after shareholder approval. All other terms, including vesting, remain unchanged.
• Ratify EisnerAmper LLP as independent auditor for FY-2025 (2024 audit fees $215k; total audit-related fees $381k).
• Authorize an adjournment if additional proxies are needed.

Share count stands at 10.78 m; the largest holder is Bios Equity entities (9.98 %). Quorum requires 33.3 % of voting power; directors are elected by plurality, other items need majority. The Board unanimously recommends FOR all proposals, citing retention and alignment benefits from the option repricing after a multi-year share-price decline (recent close $4.24). No new share issuance or financing is proposed.

Lantern Pharma Inc. (LTRN) filed a preliminary proxy (Form PRE-14A) for its virtual 2025 Annual Meeting, scheduled 19 September 2025 at 11:00 a.m. ET. Holders of record on 28 July 2025 will vote on four proposals:

• Elect six directors (current slate; five qualify as independent).
• Reprice 314,633 underwater stock options (â‰�25 % of total outstanding options). Grants with strikes >$10 will reset to $5.04â€�125 % of the 10-day VWAP—if holders remain employed/serving for 12 months after shareholder approval. All other terms, including vesting, remain unchanged.
• Ratify EisnerAmper LLP as independent auditor for FY-2025 (2024 audit fees $215k; total audit-related fees $381k).
• Authorize an adjournment if additional proxies are needed.

Share count stands at 10.78 m; the largest holder is Bios Equity entities (9.98 %). Quorum requires 33.3 % of voting power; directors are elected by plurality, other items need majority. The Board unanimously recommends FOR all proposals, citing retention and alignment benefits from the option repricing after a multi-year share-price decline (recent close $4.24). No new share issuance or financing is proposed.

Lantern Pharma Inc. (LTRN) filed a preliminary proxy (Form PRE-14A) for its virtual 2025 Annual Meeting, scheduled 19 September 2025 at 11:00 a.m. ET. Holders of record on 28 July 2025 will vote on four proposals:

• Elect six directors (current slate; five qualify as independent).
• Reprice 314,633 underwater stock options (â‰�25 % of total outstanding options). Grants with strikes >$10 will reset to $5.04â€�125 % of the 10-day VWAP—if holders remain employed/serving for 12 months after shareholder approval. All other terms, including vesting, remain unchanged.
• Ratify EisnerAmper LLP as independent auditor for FY-2025 (2024 audit fees $215k; total audit-related fees $381k).
• Authorize an adjournment if additional proxies are needed.

Share count stands at 10.78 m; the largest holder is Bios Equity entities (9.98 %). Quorum requires 33.3 % of voting power; directors are elected by plurality, other items need majority. The Board unanimously recommends FOR all proposals, citing retention and alignment benefits from the option repricing after a multi-year share-price decline (recent close $4.24). No new share issuance or financing is proposed.

Lantern Pharma Inc. (LTRN) filed a preliminary proxy (Form PRE-14A) for its virtual 2025 Annual Meeting, scheduled 19 September 2025 at 11:00 a.m. ET. Holders of record on 28 July 2025 will vote on four proposals:

• Elect six directors (current slate; five qualify as independent).
• Reprice 314,633 underwater stock options (â‰�25 % of total outstanding options). Grants with strikes >$10 will reset to $5.04â€�125 % of the 10-day VWAP—if holders remain employed/serving for 12 months after shareholder approval. All other terms, including vesting, remain unchanged.
• Ratify EisnerAmper LLP as independent auditor for FY-2025 (2024 audit fees $215k; total audit-related fees $381k).
• Authorize an adjournment if additional proxies are needed.

Share count stands at 10.78 m; the largest holder is Bios Equity entities (9.98 %). Quorum requires 33.3 % of voting power; directors are elected by plurality, other items need majority. The Board unanimously recommends FOR all proposals, citing retention and alignment benefits from the option repricing after a multi-year share-price decline (recent close $4.24). No new share issuance or financing is proposed.

Lantern Pharma Inc. (LTRN) filed a preliminary proxy (Form PRE-14A) for its virtual 2025 Annual Meeting, scheduled 19 September 2025 at 11:00 a.m. ET. Holders of record on 28 July 2025 will vote on four proposals:

• Elect six directors (current slate; five qualify as independent).
• Reprice 314,633 underwater stock options (â‰�25 % of total outstanding options). Grants with strikes >$10 will reset to $5.04â€�125 % of the 10-day VWAP—if holders remain employed/serving for 12 months after shareholder approval. All other terms, including vesting, remain unchanged.
• Ratify EisnerAmper LLP as independent auditor for FY-2025 (2024 audit fees $215k; total audit-related fees $381k).
• Authorize an adjournment if additional proxies are needed.

Share count stands at 10.78 m; the largest holder is Bios Equity entities (9.98 %). Quorum requires 33.3 % of voting power; directors are elected by plurality, other items need majority. The Board unanimously recommends FOR all proposals, citing retention and alignment benefits from the option repricing after a multi-year share-price decline (recent close $4.24). No new share issuance or financing is proposed.

On 14 Jul 2025, HA Sustainable Infrastructure Capital, Inc. (HASI) filed an 8-K announcing the appointment of Nitya Gopalakrishnan, 53, as Executive Vice President & Chief Operating Officer.

Gopalakrishnan joins from BlackRock, where she most recently served as Managing Director & Head of Investment Infrastructure, SMA Solutions, following 25 years in senior platform, engineering and COO roles. The filing states there are no related-party relationships or transactions requiring disclosure.

The offer letter sets a $400 k base salary, target annual cash bonus equal to 125 % of salary, and a 20,000-share restricted-stock sign-on grant vesting over three years. She is also eligible for annual LTIP awards (~100 % of salary) and up to $100 k relocation reimbursement.

If terminated without cause, severance includes 12-months salary, an average prior-bonus payout, one year of health benefits, and full acceleration of all unvested equity.

No other material events, financial results, or transactions were disclosed.

Verve Therapeutics, Inc. (NASDAQ: VERV) filed Post-Effective Amendment No. 3 to its automatic shelf registration (Form S-3, File No. 333-267578) to terminate the registration and deregister all unsold securities previously available under the shelf.

• The original shelf (effective Sept 23 2022) covered up to $500 million in mixed securities and an additional $150 million of common stock under an at-the-market sale agreement with Jefferies.
• On July 25 2025, Verve completed its merger with Eli Lilly and Company; Ridgeway Acquisition Corp. was merged into Verve, which now operates as an indirect wholly owned subsidiary of Lilly.
• Because the company is no longer an independent public issuer, all offerings under the shelf have been permanently terminated.

Moog Inc. (MOG) reported another solid quarter for the period ended 28 Jun 2025. Q3 net sales rose 7.4% YoY to $971.4 m, lifting nine-month sales to $2.82 bn (+4.6%). Gross profit expanded 5.7% to $265.8 m, while SG&A and R&D climbed 9.9% and -21.2% respectively. After accounting for $3 m impairment, $2.9 m restructuring and higher taxes, net earnings grew 5.9% to $59.7 m. Diluted EPS advanced to $1.87 from $1.74; nine-month diluted EPS reached $5.25 (+3.3%).

Balance-sheet metrics show total assets up 7.4% to $4.40 bn. Long-term debt jumped 24% to $1.08 bn following a new $250 m term loan; leverage therefore increased, though Moog remains covenant-compliant. Operating cash flow fell to $32.5 m (vs $46.6 m) on higher working-capital needs; capex was $103 m, producing negative free cash flow. The company returned cash via $27.2 m dividends and $128.7 m share repurchases.

Strategically, Moog closed the $84.9 m COTSWORKS acquisition (Space & Defense) and classified a non-core Space & Defense unit (assets $53.8 m) as held for sale. Backlog remains strong with $5.51 bn in remaining performance obligations, 48% convertible to revenue within 12 months. An out-of-period warranty correction increased cost of sales by $7.5 m but was deemed immaterial to prior periods.

Verve Therapeutics, Inc. ("Verve") filed Post-Effective Amendment No. 1 to five previously effective Form S-8 registration statements that in aggregate covered approximately 31.2 million shares of common stock reserved for the company’s 2018 Equity Incentive Plan, 2021 Stock Incentive Plan, Amended & Restated 2021 Employee Stock Purchase Plan, and 2024 Inducement Stock Incentive Plan.

On 25 July 2025, Verve completed its merger with Eli Lilly and Company through Ridgeway Acquisition Corporation and is now an indirect, wholly-owned Lilly subsidiary. Because Verve will no longer issue shares to the public, it has terminated all offerings under the S-8s and is deregistering any unsold shares that remained available under the equity plans. After effectiveness of these amendments, no Verve securities remain registered with the SEC pursuant to the referenced S-8 filings.

The document is purely administrative: it does not introduce new financing, earnings data, or changes to plan terms. It simply formalises the cleanup of outstanding share registrations following the closing of the Lilly transaction.